Executive Partner, Private Equity
David joined Sofinnova as an Executive Partner in 2007. He represents Sofinnova as the Chairman of NextCure, and as Director of Antiva Biosciences, Dauntless Pharmaceuticals, and Principia. He also serves as Chairman of Lineagen and as a Director of bioTheranostics. Previously he served as the Chairman of both Trius Therapeutics and Amplimmune, and as a Director of InterMune and Allylix.
Prior to Sofinnova, David spent almost 30 years in industry leading technology and product development programs in the pharmaceutical, biopharmaceutical, and drug delivery fields. David co-founded Salmedix, a developer of cancer drug treatments, and served as the company’s Chairman and Chief Executive Officer. In June 2005, he negotiated the acquisition of Salmedix by Cephalon. David also held the positions of Executive Vice President of Dura and President and Chief Executive Officer of Spiros while at Dura Pharmaceuticals, a specialty respiratory pharmaceutical and pulmonary drug delivery company. Earlier, David was also employed as Chief Executive Officer of Corvas International and held senior executive positions with Hybritech.
David received his PhD from Yale University and his BA from Case Western Reserve University.
Assistant: Lesley Weber